Please login to the form below

Not currently logged in
Email:
Password:

lesinurad

This page shows the latest lesinurad news and features for those working in and with pharma, biotech and healthcare.

Sanofi’s rare blood disorder drug Cablivi set for European approval

Sanofi’s rare blood disorder drug Cablivi set for European approval

In addition to the orphan drug approvals, the CHMP also gave positive opinions to Gruenenthal’s gout treatment Duzallo (lesinurad/allopurinol), a follow-up to the company’s Zurampic (lesinurad) product.

Latest news

More from news
Approximately 8 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2016 Deal Watch October 2016

    Gout 2016. Ironwood. Lesinurad US. $265m royalties. Rhinitis 2016. Janssen. Rhinocort outside US.

  • Deal Watch June 2016 Deal Watch June 2016

    The deal also covers a fixed dose combination of lesinurad and allopurinol which is currently in clinical trials. ... licence. 270. AstraZeneca/ Grünenthal. Zurampic (lesinurad) and lesinurad fixed-dose combo with allopurinol for hyperuricaemia in

  • Deal Watch April 2016 Deal Watch April 2016

    450. AstraZeneca (UK). Ironwood (US). US license and commercialisation. Lesinurad (approved) combo in development for treatment of gout.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics